Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Arvinas, Inc.
arvinas.comAI Executive Summary
AI-powered analysis of 8-K filing content
Arvinas entered into a license agreement with Rigel Pharmaceuticals on May 11, 2026, granting Rigel exclusive global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant). This strategic partnership expands Arvinas's licensing activities and is expected to enhance market reach and generate future revenue.
Key Takeaways
Arvinas granted Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU™, an FDA-approved PROTAC estrogen receptor degrader
The agreement involves Arvinas, its subsidiaries (Arvinas Operations, Inc. and Arvinas Estrogen Receptor, Inc.), and Pfizer Inc. as co-licensors to Rigel
2 more takeaways
Related Filings (4)
4 more filings from Arvinas, Inc. in the last 90 days